Alibaba, American Express among market cap stock movers on Monday

Investing.com – Turkey stocks were higher after the close on Monday, as gains in the Textile & Leather, Basic Metals and Non-Metal Mineral Products sectors led shares higher.

At the close in Istanbul, the BIST 100 added 0.44% to hit a new all time high.

The best performers of the session on the BIST 100 were Katilimevim Tasarruf Finansman AS (IS:KTLEV), which rose 10.00% or 2.84 points to trade at 31.24 at the close. Meanwhile, EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (IS:ECILC) added 9.99% or 9.10 points to end at 100.20 and Europower Enerji ve Otomasyon Teknolojileri Sanayi Ticaret AS (IS:EUPWR) was up 9.98% or 3.40 points to 37.48 in late trade.

The worst performers of the session were Kiler Holding AS (IS:KLRHO), which fell 9.50% or 42.00 points to trade at 400.00 at the close. Pasifik Eurasia Lojistik Dis Ticaret AS (IS:PASEU) declined 4.16% or 6.70 points to end at 154.50 and Dap Gayrimenkul Gelistirme AS (IS:DAPGM) was down 3.67% or 0.44 points to 11.56.

Rising stocks outnumbered declining ones on the Istanbul Stock Exchange by 341 to 235 and 27 ended unchanged.

Shares in Katilimevim Tasarruf Finansman AS (IS:KTLEV) rose to all time highs; up 10.00% or 2.84 to 31.24.

Gold Futures for February delivery was up 2.89% or 129.86 to $4,630.76 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in March rose 0.17% or 0.10 to hit $59.04 a barrel, while the March Brent oil contract rose 0.06% or 0.04 to trade at $63.38 a barrel.

USD/TRY was up 0.19% to 43.12, while EUR/TRY rose 0.60% to 50.40.

The US Dollar Index Futures was down 0.32% at 98.57.

Investing.com -- The staggering run for one stock may not be over, according to Lynx Equity Strategy, which argues that the memory supplier is entering its “wonder years” as demand from AI infrastructure accelerates. 

Micron Technology is the stock in question. The firm has lifted its price target to a Street-high $550, saying the stock still has 60% or more upside in 2026.

Lynx noted that Micron’s margins have surged as the supply-demand imbalance deepens, stating that “gross margin jumped ~10 percentage points in a single quarter and ~20 percentage points over two quarters.” 

The firm expects further gains as data-center configurations shift toward inference workloads. Its analysts believe Micron is at the early stages of a multiyear earnings expansion, supported by a “substantial jump in capex in FY27.”

While many on Wall Street see bullishness driven by tight supply, Lynx takes the opposite view. 

“Our multi-year positive thesis is based on just the opposite,” it wrote, predicting that new DRAM capacity will come online earlier than expected. 

The firm sees industry wafer-fab equipment spending rising 50% in 2026 and expects Micron’s own FY27 capex to double. Its checks point to “FY27 capex up ~100% y/y.”

Lynx forecasts Micron’s revenue to double from FY26 to FY28, consistent with a 40% compound annual growth rate tied to high-bandwidth memory. 

It models FY28 earnings per share of $62 and argues that “there is an easy path” to those levels as new fabs ramp and AI-driven demand remains intense.

The firm warned of volatility but expects Micron to “make a run for the mid-400s by mid-year.”

Investing.com -- Barclays downgraded DexCom and Insulet, two large-cap diabetes device makers, to Underweight as it expects rising competition in 2026 and 2027 to weigh on valuation multiples and drive underperformance versus the broader MedTech sector.

The bank said it is becoming more cautious on the insulin-intensive segment, where it sees competitive pressure building across both continuous glucose monitoring and automated insulin delivery. It expects these risks to become increasingly reflected in share prices over the next 12 months, even if near-term revenue impact remains limited.

For DexCom, Barclays pointed to Abbott steadily taking market share over recent years, first in non-insulin-intensive Type 2 diabetes and increasingly in insulin-intensive Type 1 and Type 2 patients. The bank expects competition to intensify further in 2026 and 2027, supported by Abbott’s dual-analyte sensor and its OEM agreement with Medtronic. Barclays said this dynamic is likely to pressure DexCom’s valuation multiple as investors price in a higher risk of share loss.

Insulet faces a different but emerging competitive threat. The company has historically operated without meaningful competition in the tubeless patch pump segment of automated insulin delivery. Barclays expects that to change from 2026, starting with Tandem Diabetes Care’s tubeless Mobi system, followed by Medtronic’s planned Fit patch pump in 2027 and potentially additional entrants beyond that. As with DexCom, Barclays expects the growing competitive backdrop to weigh on Insulet’s multiple rather than trigger an immediate slowdown in sales.

Alongside the downgrades, Barclays named Globus Medical, Cooper Companies and Edwards Lifesciences as its highest-conviction Overweight picks for 2026. It said it favors stocks trading below long-term average multiples with clearer paths to multiple recovery and identifiable catalysts, while limiting exposure to mature device markets with slower growth.

Barclays kept a more cautious stance on several other Overweight-rated names, including Abbott, Boston Scientific, Intuitive Surgical and Stryker, citing factors such as deal-related dilution, positioning unwind and valuation sensitivity.

Barclays set price targets of $71 for DexCom and $274 for Insulet, maintaining that intensifying competition will be the dominant factor shaping performance for both stocks into 2026.

Investing.com -- CoreWeave (NASDAQ:CRWV) stock rose 10% Monday, outperforming the broader tech sector following CEO Michael Intrator’s recent podcast appearance where he addressed criticisms about the company’s business model.

The specific reasons for the gains weren’t entirely clear, but market observers linked the movement to Intrator’s comments on the Big Technology Podcast last week, where he and Chief Strategy Officer Brian Venturo rebutted arguments about GPU useful life - a concern that has weighed on AI infrastructure companies.

The stock movement coincided with a Moody’s Ratings report released Monday projecting that at least $3 trillion will flow into data-center-related investments over the next five years. The ratings firm identified CoreWeave among six US hyperscalers expected to collectively invest $500 billion in data centers this year alone.

CoreWeave also recently announced plans to add NVIDIA Rubin technology to its AI cloud platform in the second half of 2026, positioning itself among the first cloud providers to deploy the platform for customers building agentic AI and large-scale inference workloads.

Meanwhile, Goldman Sachs analyst Gabriela Borges assumed coverage of CoreWeave with a Neutral rating and $86 price target, citing the company’s "purpose-built architecture" as providing "a significant competitive advantage against traditional hyperscalers and other neoclouds at the high end" while noting concerns about execution risks and debt levels.

Investing.com -- Northrop Grumman (NYSE:NOC) has secured a $233 million contract to manufacture and deliver a new advanced lightweight torpedo for the U.S. Navy, featuring a custom-designed warhead to increase lethality.

The defense contractor will handle integration and initial proof of manufacturing at its facility in Plymouth, Minnesota, and at the Allegany Ballistics Laboratory in Rocket Center, West Virginia.

The contract covers proof of manufacturing, qualification phases, and delivery of multiple torpedoes for qualification testing.

The new weapon, designated as MK54 MOD 2, was designed under a cooperative development agreement with the Australian Defence Force, led by the U.S. Navy. It will enhance the existing inventory of MK54 MOD 0 and MOD 1 variants with Northrop Grumman’s advanced warhead and processing capabilities.

"Northrop Grumman is leveraging over 80 years of innovative torpedo technology, combined with our capacity and speed in delivery, to accelerate the design qualification and manufacturing for the advanced lightweight torpedo," said Dave Fine, vice president of armament systems at Northrop Grumman.

Fine added that "this new weapon will provide U.S. and allied sailors with a next-generation response to counter the most advanced undersea threats."

The MK54 MOD 2 is capable of tracking, classifying, and attacking underwater targets and will operate in all ocean environments.

Northrop Grumman’s state-of-the-art facilities and technologies will allow for rapid delivery of this urgent U.S. Navy requirement. The company has nearly 100,000 employees and over 30 million square feet of manufacturing space.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com – Morocco stocks were higher after the close on Monday, as gains in the Banking, Beverage and Transport sectors led shares higher.

At the close in Casablanca, the Moroccan All Shares added 0.24%.

The best performers of the session on the Moroccan All Shares were SMI (CSE:SMI), which rose 10.00% or 470.00 points to trade at 5,171.00 at the close. Meanwhile, Miniere Touissit (CSE:CMT) added 9.83% or 170.00 points to end at 1,900.00 and Managem (CSE:MNG) was up 8.95% or 661.00 points to 8,050.00 in late trade.

The worst performers of the session were Marocaine pour le Commerce et l’Industrie Banque SA (CSE:BCI), which fell 3.04% or 19.00 points to trade at 603.00 at the close. Cartier Saada (CSE:CRS) declined 2.94% or 1.00 points to end at 33.00 and CDM (CSE:CDM) was down 2.82% or 32.00 points to 1,103.00.

Falling stocks outnumbered advancing ones on the Casablanca Stock Exchange by 35 to 21 and 9 ended unchanged.

Shares in SMI (CSE:SMI) rose to all time highs; rising 10.00% or 470.00 to 5,171.00. Shares in Managem (CSE:MNG) rose to all time highs; up 8.95% or 661.00 to 8,050.00.

Crude oil for March delivery was down 0.17% or 0.10 to $58.84 a barrel. Elsewhere in commodities trading, Brent oil for delivery in March fell 0.28% or 0.18 to hit $63.16 a barrel, while the February Gold Futures contract rose 2.77% or 124.55 to trade at $4,625.45 a troy ounce.

EUR/MAD was unchanged 0.01% to 10.75, while USD/MAD fell 0.30% to 9.21.

The US Dollar Index Futures was down 0.28% at 98.61.